Evaluation of Rifalazil in a Combination Treatment Regimen as an Alternative to Isoniazid-Rifampin Therapy in a Mouse Tuberculosis Model
The newer rifamycin, rifalazil (RLZ) (previously known as KRM-1648), has been shown in prior experiments to be a highly potent drug against Mycobacterium tuberculosis. In this report, we studied the efficacy of RLZ in combination with pyrazinamide (PZA) and ethambutol (EMB) in a long-term in vivo ex...
保存先:
| 出版年: | Antimicrob Agents Chemother |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
American Society for Microbiology (ASM)
2000
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC101623/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/11036043/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.44.11.3167-3168.2000 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|